“Can ImaginAb's CD8 ImmunoPET imaging platform become the standard non-invasive biomarker for monitoring immune response in immunotherapy clinical trials worldwide?”
ImaginAb is a pioneering biotech company headquartered in Calabasas, California, founded by Dr. Anna Wu, focused on radiopharmaceutical imaging solutions for immuno-oncology. Its lead product, CD8 ImmunoPET (89Zr crefmirlimab berdoxam), uses 'minibody' antibodies to non-invasively image CD8 T-cells in patients undergoing immunotherapy. In January 2025, ImaginAb divested its broader biologics technology platform and therapeutic pipeline assets to Telix Pharmaceuticals, sharpening its focus exclusively on advancing the CD8 ImmunoPET imaging candidate through Phase 2 clinical trials and licensing it to pharmaceutical and biotech partners.
ImaginAb was founded by Dr. Anna Wu and is headquartered in Calabasas, CA 91302, USA.
Get a read on where your own stack stands against ImaginAb and the rest of its category — what they built versus bought, which providers they use, and where the gaps in your own strategy and competitive set actually are.